OverviewChartNewsTraderScreen

Essex Bio-Technology Ltd/  KYG312371035  /

Hong Kong SE
4/25/2025  10:08:21 AM Chg. -0.02 Volume Bid10:08:21 AM Ask10:08:21 AM High Low
4.38HKD -0.45% 542,000
Turnover: 2.22 mill.		 4.38Bid Size: 2,000 4.39Ask Size: 2,000 4.60 4.35
GlobeNewswire 3/29/2019 AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PD™ Conference
GlobeNewswire 3/21/2019 AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update
GlobeNewswire 3/4/2019 AC Immune to Report Progress of Early-Stage Pipeline at AD/PD™ Congress
GlobeNewswire 2/20/2019 AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer...
GlobeNewswire 2/7/2019 AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development
GlobeNewswire 1/3/2019 AC Immune Announces Appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer
GlobeNewswire 12/19/2018 AC Immune and WuXi Biologics to Establish an Exclusive Strategic Partnership
GlobeNewswire 12/7/2018 In Memoriam: Dr. Andreas Muhs CSO, Scientific Leader and Friend has Passed Away
GlobeNewswire 11/15/2018 AC Immune Awarded Third Follow-up Grant from The Michael J. Fox Foundation for First-in-Human Study ...
GlobeNewswire 11/13/2018 AC Immune Reports Third Quarter 2018 Financial Results and Corporate Update
GlobeNewswire 11/1/2018 AC Immune to Present at 2018 Society for Neurosciences Meeting
GlobeNewswire 10/22/2018 AC Immune Announces Dr. Andreas Muhs, Chief Scientific Officer, to Take Medical Leave of Absence
GlobeNewswire 9/19/2018 Antibody Discovery Services and Platforms Market, 2028
GlobeNewswire 8/20/2018 AC Immune Announces Important Clinical Milestones for ACI-24 Vaccine in Alzheimer's Disease and Dow...
GlobeNewswire 8/8/2018 AC Immune Reports Second Quarter 2018 Financial Results and Corporate Update
GlobeNewswire 7/25/2018 New Phase 2 Data Analysis for Crenezumab Presented at Global Alzheimer's Conference Provides Strong ...
GlobeNewswire 7/17/2018 Crenezumab's Second Phase 3 Trial (CREAD 2) Fully Recruited - Updates on AC Immune's Pipeline and Te...
GlobeNewswire 7/6/2018 AC Immune Announces Results of Annual General Meeting
GlobeNewswire 5/2/2018 AC Immune Reports First Quarter 2018 Financial Results and Corporate Update
GlobeNewswire 4/27/2018 AC Immune Announces Results of Extraordinary Shareholders Meeting
GlobeNewswire 4/5/2018 AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer's dis...
GlobeNewswire 3/20/2018 AC Immune reports full-year 2017 financial results - successful first year as a public company
GlobeNewswire 3/15/2018 AC Immune prepares for a first in human study of a promising positron emission tomography (PET) trac...
GlobeNewswire 2/6/2018 AC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD Con...
GlobeNewswire 12/1/2017 AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Tar...